Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib,…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with pembrolizumab, in patients with advanced…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response…
ATLANTA, June 14, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by…
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter of 2023 LAS VEGAS, NV…
DENVER, June 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions…
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agencyPAX-101 internally developed supply chain entering final stagesTARRYTOWN, NY, June 14, 2023…
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”) versus $10.7 million for the…